Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection

被引:111
|
作者
Browning, J
Horner, JW
Pettoello-Mantovani, M
Raker, C
Yurasov, S
DePinho, RA
Goldstein, H
机构
[1] Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA
[2] Yeshiva Univ Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10461 USA
关键词
D O I
10.1073/pnas.94.26.14637
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
HIV entry into human cells is mediated by CD4 acting in concert with one of several members of the chemokine receptor superfamily. The resistance to HIV infection observed in individuals with defective CCR5 alleles indicated that this particular chemokine receptor plays a crucial role in the initiation of in vivo HIV infection. Expression of human CD4 transgene does not render mice susceptible to HIV infection because of structural differences between human and mouse CCR5. To ascertain whether expression of human CD4 and CCR5 is sufficient to make murine T Lymphocytes susceptible to HIV infection, the lck promoter was used to direct the T cell-specific expression of human CD4 and CCR5 in transgenic mice. Peripheral blood mononuclear cells and splenocytes isolated from these mice expressed human CD4 and CCR5 and were infectible with selected M-tropic HIV isolates. After in vivo inoculation, HIV-infected cells were detected by DNA PCR in the spleen and lymph nodes of these transgenic mice, but HIV could not be cultured from these cells. This indicated that although transgenic expression of human CD4 and CCR5 permitted entry of HIV into the mouse cells, significant HIV infection was prevented by other blocks to HIV replication present in mouse cells. In addition to providing in vivo verification for the important role of CCR5 in T lymphocyte HIV infection, these transgenic mice represent a new in vivo model for understanding HIV pathogenesis by delineating species-specific cellular factors required for productive in vivo HIV infection. These mice should also prove useful for the assessment of potential therapeutic and preventative modalities, particularly vaccines.
引用
收藏
页码:14637 / 14641
页数:5
相关论文
共 50 条
  • [41] Expression of functional HIVCXCR4, CCR5, and CD4 receptors on fresh and cultured human Langerhans cells
    Tchou, I
    Misery, L
    Sabido, O
    Moja, P
    Hamzeh, H
    Peguet-Navarro, J
    Schmitt, D
    Genin, C
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 117 (04) : 1018 - 1018
  • [42] HIV Inhibition by CD4 and CCR5-Derived Glycopeptides
    Perdomo, Maria F.
    Sallberg, Matti
    Vahlne, Anders
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2012, 28 (09) : 852 - 858
  • [43] Cell-free HIV type 1 infection is restricted in the human trophoblast choriocarcinoma BeWo cell line, even with expression of CD4, CXCR4 and CCR5
    Dolcini, G
    Derrien, M
    Chaouat, G
    Barré-Sinoussi, F
    Menu, E
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2003, 19 (10) : 857 - 864
  • [44] GBV-C co-infection in HIV patients is associated with low CCR5 and CXCR4 surface expression on CD4 cells
    Schwarze-Zander, Carolynne
    Neibecker, Markus
    Othman, Sabrina
    Welzel, Carolin
    Schulz, Monika
    Voigt, Esther
    Vogel, Martin
    Wasmuth, Jan-Christian
    Luechters, Guido
    Sauerbruch, Tilmian
    Rockstroh, Juergen
    Spengler, Ulrich
    HEPATOLOGY, 2007, 46 (04) : 891A - 891A
  • [45] HIV pseudovirion vaccine exposing Env "fusion intermediates"-Response to immunisation in human CD4/CCR5-transgenic rats
    Bosch, Valerie
    Pfeiffer, Tanya
    Devitt, Gerard
    Allespach, Ina
    Ebensen, Thomas
    Emerson, Vanessa
    Guzman, Carlos A.
    Keppler, Oliver T.
    VACCINE, 2009, 27 (16) : 2202 - 2212
  • [46] CD4 signaling induced by IL-16 is enhanced by CCR5 expression
    Lynch, E
    Heijens, C
    Horst, N
    Cruikshank, W
    FASEB JOURNAL, 2003, 17 (07): : C65 - C65
  • [47] CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression
    Reynes, J
    Portales, P
    Segondy, M
    Baillat, V
    André, P
    Avinens, O
    Picot, MC
    Clot, J
    Eliaou, JF
    Corbeau, P
    AIDS, 2001, 15 (13) : 1627 - 1634
  • [48] Treatment of HIV infection with the CCR5 antagonist maraviroc
    Kromdijk, Wiete
    Huitema, Alwin D. R.
    Mulder, Jan Willem
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (07) : 1215 - 1223
  • [49] Dynamical behavior and interaction study of CD4 and CCR5 receptors by FRAPrv and FRET
    Baker, Aurelie
    Gaibelet, Gerald
    Dumas, Fabrice
    Planchenault, Thierry
    Lagane, Bernard
    Mazeres, Serge
    Bachelerie, Francoise
    Salome, Laurence
    Lopez, Andre
    BIOPHYSICAL JOURNAL, 2007, : 391A - 391A
  • [50] CCR5 and HIV infection, a view from Brussels
    Parmentier, Marc
    FRONTIERS IN IMMUNOLOGY, 2015, 6